Program
rosuvastatin
Also written as “Rosuvastatin”, “CKD-828, D097, D337” and “Rosuvastatin 20mg”.
Its studies are mostly in Hypercholesterolemia · Hypertension · Dyslipidemias · Hyperlipidemias · Coronary Artery Disease, led by 27 companies.
Drug pageRosuvastatin: every studyMany companies study it; this page follows only the 138 they lead. All 405 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 705 open or running | phase 4since Oct 7, 2005 | Sep 16, 2005 | Jan 25, 2027phase 1 · NCT07534592 |
| Yuhanits history only | 100 open or running | phase 4since Jul 12, 2017 | Jan 5, 2012 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 80 open or running | phase 2since Nov 27, 2016 | Jan 24, 2014 | none ahead |
| Organonits history only | 60 open or running | phase 4since Mar 31, 2008 | Aug 25, 2004 | none ahead |
| GlaxoSmithKlineits history only | 40 open or running | phase 1since Dec 18, 2008 | Dec 18, 2008 | none ahead |
| Merckits history only | 40 open or running | phase 3since Oct 10, 2025 | Jun 17, 2015 | none ahead |
| Hanlim Pharm.its history only | 30 open or running | phase 3since Jun 17, 2018 | Jun 17, 2018 | none ahead |
| IlDong Pharmaceuticalits history only | 30 open or running | phase 3since Mar 5, 2014 | Mar 5, 2014 | none ahead |
| Jeil Pharmaceuticalits history only | 30 open or running | phase 3since Jun 23, 2016 | Jul 4, 2014 | none ahead |
| Lotus Pharmaceuticalits history only | 30 open or running | phase 3since May 13, 2015 | Mar 4, 2014 | none ahead |
| Celltrionits history only | 20 open or running | phase 3since Apr 27, 2026 | Jul 30, 2021 | none ahead |
| Daewon Pharmaceuticalits history only | 20 open or running | phase 3since Oct 12, 2016 | Oct 12, 2016 | none ahead |
| Daewoong Pharmaceuticalits history only | 20 open or running | phase 3since Nov 7, 2019 | Mar 14, 2014 | none ahead |
| Daiichi Sankyoits history only | 20 open or running | phase 1since Sep 11, 2025 | Sep 11, 2025 | none ahead |
| Hanmi Pharmaceuticalits history only | 20 open or running | phase 1since Mar 9, 2014 | Mar 9, 2014 | none ahead |
| kobe-universityits history only | 20 open or running | phase 4since Jun 15, 2017 | Jun 15, 2017 | none ahead |
| LG Chemits history only | 20 open or running | phase 3since Aug 5, 2013 | Aug 5, 2013 | none ahead |
| Ache Laboratorios Farmaceuticosits history only | 10 open or running | phase 3since Aug 18, 2011 | Aug 18, 2011 | none ahead |
| d16-pharma-biotec-ltdits history only | 10 open or running | phase 4since Jun 4, 2012 | Jun 4, 2012 | none ahead |
| Dong-A STits history only | 10 open or running | phase 4since Oct 29, 2014 | Oct 29, 2014 | none ahead |
| Hansoh Pharmaceutical Groupits history only | 11 open or running | phase 1since May 23, 2025 | May 23, 2025 | none ahead |
| HK inno.Nits history only | 10 open or running | phase 4since Nov 20, 2018 | Nov 20, 2018 | none ahead |
| hyundai-pharmits history only | 11 open or running | phase 3since Oct 15, 2024 | Oct 15, 2024 | none ahead |
| Jiangsu HengRui Medicineits history only | 10 open or running | phase 1since May 27, 2020 | May 27, 2020 | none ahead |
| NVP Healthcareits history only | 10 open or running | phase 1since Nov 9, 2014 | Nov 9, 2014 | none ahead |
| pin-siang-medical-biotechnology-co-ltdits history only | 10 open or running | no phasesince Nov 6, 2013 | Nov 6, 2013 | none ahead |
| verisfield-uk-ltd-greek-branchits history only | 10 open or running | phase 1since May 9, 2016 | May 9, 2016 | none ahead |
Also a collaborator on its studies: Parexel, Pharma Medica Research, Pfizer, Regeneron Pharmaceuticals, Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene, Eli Lilly, Linical Korea and Shionogi.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AstraZeneca only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Oct 16, 2005.
- Nov 4, 2016Phase 1 study in High Risk Coronary Artery DiseaseNCT02963116 · 12 enrolled · United Kingdom
- Jan 11, 2017Phase 1 study in HealthyNCT03019549 · 42 enrolled · United States
- May 17, 2022Phase 1 study in DyslipidemiasNCT05384262 · 183 enrolled · United States, United Kingdom
- Mar 3, 2023Phase 1 study in Healthy Male SubjectsNCT05768360 · 6 enrolled · Germany
- Nov 29, 2023Phase 1 study in HealthyNCT06160414 · 20 enrolled · United Kingdom
- Aug 2, 2024Phase 1 study in Healthy ParticipantsNCT06554821 · 28 enrolled · Germany
- Dec 2, 2024Phase 3 study in DyslipidemiasNCT06834932 · 432 enrolled · China, Hong Kong
- Dec 16, 2024Phase 1 study in DyslipidemiasNCT06742853 · 81 enrolled · United States, United Kingdom
- Jul 17, 2025Phase 1 study in Healthy ParticipantsNCT07088913 · 20 enrolled · United States
- Dec 19, 2025Phase 1 study in HyperlipidemiasNCT07316608 · 44 enrolled · United States
- Apr 10, 2026Phase 1 study in Diabetes Mellitus, Type 2NCT07534592 · 48 enrolled · United States
- May 26, 20262 phase 3 studies in HypercholesterolemiaNCT07619131, NCT07619118
- Nov 5, 2026Phase 3 study in HypercholesterolemiaNCT07930507 · 204 planned · China, Hong Kong, Malaysia and more
- Nov 10, 2026Primary completion moved from 2026-10-01 to 2027-01-25Date moved laterphase 1 · +4 months · NCT07534592
Ahead
- Jan 25, 2027Primary completion: phase 1 study in Diabetes Mellitus, Type 2NCT07534592
- Feb 22, 2027Primary completion: phase 3 study in DyslipidemiasNCT06834932
- May 28, 2027Primary completion: phase 3 study in HypercholesterolemiaNCT07619118
- Jul 30, 2027Primary completion: phase 3 study in HypercholesterolemiaNCT07619131
TargetBeta
“HMG-CoA reductase inhibitor”ChEMBL 37, by rule
Other programs on HMGCR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Atorvastatinrule | Viatris | phase 4 | 186 |
| Simvastatinrule | Organon | phase 4 | 100 |
| pitavastatinrule | Kowa | phase 4 | 36 |
Studies
The newest 60 of 70 AstraZeneca leads. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07930507Hypercholesterolemia · China, Hong Kong, Malaysia and more | 3 | Not yet recruiting | Oct 11, 2027 | 204 |
| NCT07619131Hypercholesterolemia · United States, Bulgaria, Canada and more | 3 | Recruiting | Jul 30, 2027 | 600 |
| NCT07619118Hypercholesterolemia · United States, Australia, Canada and more | 3 | Recruiting | May 28, 2027 | 200 |
| NCT07534592Diabetes Mellitus, Type 2 · United States | 1 | Active, not recruiting | Jan 25, 2027 | 48 |
| NCT07316608Hyperlipidemias · United States | 1 | Completed | Jun 5, 2026 | 44 |
| NCT07088913Healthy Participants · United States | 1 | Completed | Feb 20, 2026 | 20 |
| NCT06742853Dyslipidemias · United States, United Kingdom | 1 | Completed | Oct 29, 2025 | 81 |
| NCT06834932Dyslipidemias · China, Hong Kong | 3 | Active, not recruiting | Feb 22, 2027 | 432 |
| NCT06554821Healthy Participants · Germany | 1 | Completed | Oct 8, 2024 | 28 |
| NCT06160414Healthy · United Kingdom | 1 | Completed | Feb 5, 2024 | 20 |
| NCT05768360Healthy Male Subjects · Germany | 1 | Completed | Jun 24, 2023 | 6 |
| NCT05384262Dyslipidemias · United States, United Kingdom | 1 | Completed | Jun 14, 2024 | 183 |
| NCT03019549Healthy · United States | 1 | Completed | May 22, 2017 | 42 |
| NCT02963116High Risk Coronary Artery Disease · United Kingdom | 1 | Completed | Mar 1, 2017 | 12 |
| NCT02859129Hypertriglyceridemia · United States | 1 | Completed | Nov 2013 | 114 |
| NCT02546323Atherosclerosis · China | 3 | Completed | Jan 29, 2019 | 543 |
| NCT02434497Homozygous Familial Hypercholesterolemia · Belgium, Canada, Denmark and more | 3 | Completed | Nov 17, 2016 | 9 |
| NCT02226198Homozygous Familial Hypercholesterolemia · Belgium, Canada, Denmark and more | 3 | Completed | Jul 2015 | 20 |
| NCT01164540Venous Thrombosis | 3 | Withdrawn | Mar 2013 | 3,000 |
| NCT01078675Hyperlipoproteinemia Type II · United States, Belgium, Canada and more | 3 | Completed | Feb 2013 | 315 |
| NCT00815659Metabolic Syndrome · Turkey | 4 | Completed | Mar 2010 | 97 |
| NCT00800800Aortic Valve Stenosis · Canada | 3 | Completed | Sep 2008 | 378 |
| NCT00783042Atherosclerosis · Sweden | Early 1 | Completed | 80 | |
| NCT00766025CYP2C19 Poor · Taiwan | 1 | Completed | 50 | |
| NCT00747149Diabetes Mellitus, Type 2 · Canada | 4 | Completed | Aug 2009 | 598 |
| NCT00689416Atherosclerosis · Sweden | Early 1 | Completed | 74 | |
| NCT00683618Hypercholesterolemia · China | 3 | Completed | Jul 2009 | 934 |
| NCT00657527Coronary Artery Disease | 3 | Completed | 280 | |
| NCT00654602Dyslipidemias | 3 | Completed | 1,500 | |
| NCT00654537Hypercholesterolemia | 3 | Completed | 5,625 | |
| NCT00654485Metabolic Syndrome | 3 | Completed | 940 | |
| NCT00654446Dyslipidemias | 3 | Completed | 442 | |
| NCT00654407Hypercholesterolemia | 3 | Completed | 4,875 | |
| NCT00654394Carotid Stenosis | 3 | Completed | 200 | |
| NCT00654303Hypercholesterolemia | 3 | Completed | 3,500 | |
| NCT00653588Hypercholesterolemia | 3 | Completed | ||
| NCT00653445Hypercholesterolemia | 3 | Completed | ||
| NCT00654225Hypercholesterolemia | 3 | Completed | 2,340 | |
| NCT00654173Hypercholesterolemia | 3 | Completed | 4,444 | |
| NCT00653965Hypercholesterolemia | 3 | Completed | 3,000 | |
| NCT00653744Hypercholesterolemia | 3 | Completed | 1,700 | |
| NCT00620542Coronary Artery Disease · United States, Argentina, Australia and more | 3 | Completed | Jun 2011 | 2,333 |
| NCT00525824Hypercholesterolemia · United States, Argentina, Brazil and more | 3 | Completed | Sep 2008 | 1,743 |
| NCT00473655Hypertriglyceridemia · Mexico | 4 | Completed | Feb 2009 | 334 |
| NCT00427960Hypercholesterolemia · United Kingdom | 4 | Terminated | Feb 2008 | 55 |
| NCT00396240Hypercholesterolemia | 4 | Withdrawn | 1,294 | |
| NCT00395486Metabolic Syndrome · Korea, Republic of | 4 | Completed | Jun 2008 | 258 |
| NCT00379249Hypercholesterolemia | 3 | Completed | 8,000 | |
| NCT00355615Hyperlipoproteinemia Type II · United States, Canada, Netherlands and more | 3 | Completed | Jul 2008 | 173 |
| NCT00335699Hypercholesterolemia · Korea, Republic of | 4 | Completed | 370 | |
| NCT00329173Hypercholesterolemia | 3 | Completed | 1,000 | |
| NCT00329160Hypercholesterolemia · Japan | 4 | Completed | Oct 2008 | 214 |
| NCT00296400Hyperlipidemias · United States, Brazil, Bulgaria and more | 2 | Completed | Jun 2009 | 237 |
| NCT00296387Acute Coronary Syndrome · Belgium, Canada, Estonia and more | 3 | Completed | 1,160 | |
| NCT00296374Diabetes Mellitus · United States, Argentina, Brazil and more | 2 | Completed | Mar 2009 | 353 |
| NCT00262548Diabetes Mellitus, Type 2 · Mexico | 4 | Completed | 100 | |
| NCT00241488Hypercholesterolemia · China, Hong Kong, Korea, Republic of and more | 3 | Completed | Dec 2005 | 1,362 |
| NCT00240331Renal Insufficiency · Australia, Austria, Belgium and more | 3 | Completed | Oct 2008 | 2,776 |
| NCT00240318Coronary Artery Disease · United States, Australia, Belgium and more | 3 | Completed | Nov 2005 | 450 |
| NCT00240305Metabolic Syndrome · Australia | 3 | Completed | 15 |
How it is read
Names in the registry
- “Rosuvastatin”, 105 entries
- “rosuvastatin”, 10 entries
- “CKD-828, D097, D337”, 6 entries
- “Rosuvastatin 20mg”, 6 entries
- “Ezetimibe/Rosuvastatin”, 4 entries
Conditions, from the studies’ own filings
- Hypercholesterolemia, 43 studies
- Hypertension, 23 studies
- Dyslipidemias, 9 studies
- Hyperlipidemias, 6 studies
- Coronary Artery Disease, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.